Neurosense Therapeutics Ltd expected to post a loss of 28 cents a share - Earnings Preview

Neurosense Therapeutics

21/07/2023 08:07

* Neurosense Therapeutics Ltd  NRSN.OQ   NRSN.O  is expected
to report results on July 25 (estimated).
    * 
    * ​Refinitiv's mean analyst estimate for Neurosense
Therapeutics
Ltd is for a loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Buy".​
    * Wall Street's median 12-month price target for Neurosense
Therapeutics Ltd is $7.25​, above​ its last closing price
of $1.43. ​​​

This summary was machine generated July 21 at 07:07 GMT.  All
figures in US dollars  unless otherwise stated